These biomarkers were comprised of well characterized cell cycle (p53, p21, mdm2) and cell death (p53, bax, bcl-xL, bcl-2, bin1, CD95, NFkB) regulators variably expressed by human prostate cancers [5,10-16]. Here, BCL2L1 is linked to prostate carcinoma.